Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 03, 2015 7:29 AM ET

Healthcare Equipment and Supplies

Company Overview of Entellus Medical, Inc.

Company Overview

Entellus Medical, Inc., a medical technology company, focuses on the design, development, and commercialization of products for the minimally invasive treatment of patients suffering from chronic sinusitis. The company offers XprESS Multi-Sinus Dilation family of products consisting of XprESS Pro device, XprESS LoProfile device, and XprESS Ultra device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation; and FinESS sinus dilation system, a solution for treatment of the maxillary sinus drainage pathway. It also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides real-time high intensity red tra...

3600 Holly Lane North

Suite 40

Plymouth, MN 55447

United States

Founded in 2006

177 Employees



Key Executives for Entellus Medical, Inc.

Chief Executive Officer, President and Director
Age: 53
Total Annual Compensation: $93.0K
Executive Chairman
Age: 58
Total Annual Compensation: $458.9K
Vice President of Clinical, Regulatory & Quality and Compliance Officer
Age: 56
Total Annual Compensation: $240.0K
Vice President of Sales
Age: 48
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2014.

Entellus Medical, Inc. Key Developments

Entellus Medical, Inc. Announces Collaboration with Fiagon NA Corporation

Entellus Medical, Inc. announced a collaboration with Fiagon NA Corporation. The agreement enables Entellus to be the exclusive distributor of Fiagon Image Guidance Systems ("IGS") for ENT offices and ENT Ambulatory Surgery Centers in the United States. The company expects the integration of the Entellus XprESS Pro Multi-Sinus Dilation System and the Fiagon IGS to provide another level of confirmation to increase physician confidence in device placement. Entellus Medical's systems deliver proven results that are equivalent to those obtained through traditional sinus surgery, while at the same time providing an improved patient experience. The addition of the Fiagon IGS in the office setting has the potential to continue the expansion of ENT surgical procedures into the office setting through positive clinical outcomes and reduced costs to both the patient and healthcare system.

Entellus Medical, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Third Quarter and Full Year of 2015

Entellus Medical, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, revenue was $15,191,000 against $12,498,000 a year ago. Loss from operations was $2,354,000 against $651,000 a year ago. Net loss was $2,868,000 or $0.15 per basic and diluted share against $1,173,000 or $0.81 per basic and diluted share a year ago. For six months, revenue was $28,693,000 against $22,673,000 a year ago. Loss from operations was $5,804,000 against $2,770,000 a year ago. Net loss was $7,216,000 or $0.46 per basic and diluted share against $3,708,000 or $2.59 per basic and diluted share a year ago. The company estimates that third quarter 2015 revenue will range from approximately $13.9 million to $14.4 million, which would represent growth of approximately 19% to 23% versus the third quarter of 2014. The company expects that gross margin for the third quarter of 2015 will range from 77.5% to 78.5% compared to 78.6% in the third quarter of 2014. Third quarter net loss is estimated to range from approximately $3.7 million to $5.3 million, or an estimated net loss of $0.20 to $0.28 per share. The estimated net loss for the third quarter includes estimated non-cash stock-based compensation of $0.7 million to $0.8 million. The company continues to expect full year 2015 revenue will be in a range of $58.5 million to $61.0 million, representing growth of 20% to 25% annually, and that gross margin will be in a range of 77% to 78% for 2015. Full year 2015 net loss is expected to be in a range of $14.0 million to $19.0 million, or a net loss of $0.80 to $1.10 per share.

Entellus Medical, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Entellus Medical, Inc. announced that they will report Q2, 2015 results After-Market on Aug 06, 2015

Similar Private Companies By Industry

Company Name Region
Med-Safe Systems, Inc. United States
Apnex Medical, Inc. United States
VersaMed Medical Systems, LLC United States
Tayman Medical Inc. United States
LAFORGE Optical Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Entellus Medical, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at